STOCK TITAN

Armistice Capital reports 4.99% stake in VolitionRx (VNRX) — 6.45M shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

VOLITIONRX LTD filing an amendment to a Schedule 13G reporting beneficial ownership of 6,449,635 common shares, representing 4.99% of the class. The filing attributes that position to Armistice Capital, LLC as investment manager of Armistice Capital Master Fund Ltd., with shared voting and dispositive power over those 6,449,635 shares. The statement is a joint filing that also names Steven Boyd and is signed on 02/17/2026.

Positive

  • None.

Negative

  • None.

Insights

Armistice Capital reports a passive sub-5% stake with shared control.

The amendment lists 6,449,635 shares beneficially owned, equal to 4.99% of common stock as reported. The filing states shared voting and shared dispositive power over those shares, reflecting investment-manager control on behalf of the Master Fund.

Holder decisions will determine any future disclosures or Form 13D triggers; timing and any trading plans are not stated in the provided excerpt.

Amendment clarifies beneficial ownership and joint-filing attribution under Rule 13d-1(k).

The filing explains that Armistice Capital is investment manager to the Master Fund and that Mr. Boyd may be deemed to beneficially own the securities due to his role. The Master Fund disclaims direct beneficial ownership based on its contractual inability to vote or dispose.

The signature block shows the amendment dated 02/17/2026; no statements about plans to buy or sell are included in the excerpt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: Feburary 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in VOLITIONRX (VNRX)?

Armistice Capital reports beneficial ownership of 6,449,635 shares, representing 4.99% of common stock. The filing attributes shared voting and dispositive power over those 6,449,635 shares to Armistice as investment manager.

Who is listed as the reporting persons on the Schedule 13G/A for VNRX?

The reporting persons are Armistice Capital, LLC and Steven Boyd. The filing is a joint statement filed on behalf of both and signed by Steven Boyd on 02/17/2026.

Does the Schedule 13G/A indicate Armistice controls voting of the shares?

The filing states Armistice Capital exercises shared voting power and shared dispositive power over the 6,449,635 shares held by the Master Fund under an Investment Management Agreement.

Does the Master Fund claim beneficial ownership of the VNRX shares?

The Master Fund is identified as the direct holder, but the filing states the Master Fund specifically disclaims beneficial ownership

When was the Schedule 13G/A amendment signed?

The joint amendment is signed by Steven Boyd with a signature date of 02/17/2026. The header shows a reference date of 12/31/2025 in the filing excerpt.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

30.73M
79.79M
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON